Market Overview

of Global Retinal Biologics market:
The latest research study on the global Retinal Biologics market finds that the global Retinal Biologics market reached a value of USD 14413.0 million in 2022. It’s expected that the market will achieve USD 28995.83 million by 2028, exhibiting a CAGR of 12.36% during the forecast period.

Biologics are generally produced from living organisms such as microorganisms, or animal or plant cells. Retinal biologics refer to bioengineered molecules which are implanted inside the eyes in order to heal chronic retinal diseases.

Licensing and cooperation agreements between major players to expand product coverage
Many companies are signing licensing and cooperation agreements to expand their products to countries around the world to meet unmet demand. For example, in August 2021, Polpharma Biologics Group announces that its joint venture company with Santo Holding, Bioeq, has submitted a biologics license application (BLA) to the US Food and Drug Administration (FDA) for their biosimilar candidate of the ophthalmological drug Ranibizumab (Lucentis®).
In order to improve the R&D pipeline portfolio, many companies have signed cooperation agreements with various other companies and universities, which are expected to promote the development of the retinal biologics market during the forecast period.

Side effects and disadvantages of retinal biologics
When retinal biologics is used to treat retinal diseases, it may produce certain side effects, which will bring challenges to its market development. Serious side effects of retinal biologics may lead to eye infection, permanent decline of vision, increase of intraocular pressure, formation or deterioration of cataract, etc. The most common side effects are red eyes, cataract, eye swelling, irritation or pain.

The economic burden of drug development for enterprises is heavy
The economic burden of the development of retinal biologics is heavy. Therefore, many companies are generally not interested in the research and development of retinal biologics. The market participants of retinal biologics are mainly concentrated in Europe and the United States, which is mainly due to the support policies of developed countries for the development of retinal biologics. Overseas policies mainly include fee reduction and exemption, financial support, R & D assistance, priority review, market exclusivity, etc., which has greatly stimulated the enthusiasm of pharmaceutical enterprises to develop retinal biologics. However, this factor will also bring challenges to its market development.

Region Overview:
In 2022, the share of the Retinal Biologics market in North America stood at 50.65%.

Company Overview:
Regeneron Pharmaceuticals, Inc is one of the major players operating in the Retinal Biologics market, holding a share of 37.8% in 2023.

Regeneron Pharmaceuticals, Inc
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP.

Bayer
Bayer is a company focusing on seeds, crop protection, and non-agricultural pest control. It develops genetically modified crops and pesticides. Bayer serves customers worldwide.

Segmentation Overview:
As for product types, the Macular Degeneration segment held the largest market share in 2022.

Macular Degeneration
Macular degeneration is characterized by progressive degeneration of the macula, the central part of the retina, leading to central vision loss. The current treatment for macular degeneration is the injection of anti-VEGF medication into each affected eye. Three anti-VEGF biologics are currently available: the VEGF-decoy aflibercept (Eylea), antibody fragments ranibizumab (Lucentis), and brolucizumab (Beovu).

Diabetic Retinopathy
Diabetic retinopathy usually only requires specific treatment when it reaches an advanced stage and there's a risk to patients' vision. In some cases of diabetic maculopathy, injections of a medicine called anti-VEGF may be given directly into patients' eyes to prevent new blood vessels forming at the back of the eyes.

Diabetic Macular Edema
Diabetic macular edema (DME) is one of the main causes of visual impairment in persons with diabetic retinopathy. Owing to the efficacy and safety profile of anti-VEGF therapy, it has become the first-line treatment. Besides ranibizumab and aflibercept, bevacizumab demonstrated efficacy in the treatment of DME.

Uveitis
Uveitis is characterized by intraocular inflammation affecting the uveal structures of the eye, including the iris, ciliary body, and choroid. The success in rheumatology of the TNF-α inhibitors adalimumab (ADA) and infliximab (IFX) over the past several years has led to their use in uveitis.

Application Overview:
The market's largest segment by application is the segment Hospitals, with a market share of 68.01% in 2022.

The report covers a research time span from 2018 to 2029; combines extensive quantitative analysis and exhaustive qualitative analysis; presents not only an overview of the global Retinal Biologics market in metrics of sales, revenue, growth rate, but also a deeper dive into the segmented market by region, product type and downstream industry, showing the readers a clear and distinct picture of how the market is distributed from different perspectives.

For competitive landscape, prominent players with considerable market shares are comprehensively analyzed in this report. With information regarding the concentration ratio and detailed data reflecting the market performance of each player shared, the readers can acquire a holistic view of the competitive situation and a better understanding of their competitors.

As the COVID-19 takes over the world, we are continuously tracking the changes in the markets. We analyzed the impact of the pandemic in detail, along with other key factors, such as macro-economy, regional conflicts, industry related news and policies. Meanwhile, market investment scenario, technology status and developments, supply chain challenges, among other essential research elements are all covered.

Research Scope
This report provides an overview of the global Retinal Biologics market and analyzes the segmented market by product type, downstream industry, and region, presenting data points such as sales, revenue, growth rate, explaining the current status and future trends of the Retinal Biologics and its sub-markets in an intuitive way.

Key Companies in the global Retinal Biologics market covered in Chapter 3:
AbbVie Inc
Roche
Johnson & Johnson Services, Inc
Novartis
Regeneron Pharmaceuticals, Inc
Amgen Inc
Bayer

In Chapter 4 and Chapter 14.2, on the basis of types, the Retinal Biologics market from 2018 to 2029 is primarily split into:
Macular Degeneration
Diabetic Retinopathy
Diabetic Macular Edema
Uveitis
Others

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Retinal Biologics market from 2018 to 2029 covers:
Hospitals
Clinics
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:
North America (United States, Canada)

Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)

Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)

Latin America (Brazil, Mexico, Argentina)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)

Key Factors Considered

COVID-19
Amid the COVID-19 crisis, the Retinal Biologics market has definitely taken a hit. The report describes the market scenario during and post the pandemic in the vision of upstream raw materials, major market participants, downstream major customers, etc. Other aspects, such as changes in consumer behavior, demand, transport capacity, trade flow under COVID-19, have also been taken into consideration during the process of the research.

Regional Conflict / Russia-Ukraine War
The report also presents the impact of regional conflict on this market in an effort to aid the readers to understand how the market has been adversely influenced and how it’s going to evolve in the years to come.

Challenges & Opportunities
Factors that may help create opportunities and boost profits for market players, as well as challenges that may restrain or even pose a threat to the development of the players, are revealed in the report, which can shed a light on strategic decisions and implementation.

Chapter Outline

Chapter 1 starts the report with a brief overview of the research scope, as well as the definitions of the target market and the subdivisions.

Chapter 2 integrates and sketches the research findings and conclusions in a clear and explicit way.

Chapter 3 presents the competitive landscape by displaying the sales, revenue, and market shares of the top players. It also profiles the major market participants with their business introductions, sales, price, revenue, gross, growth rates, etc.

Chapter 4 breaks down the market by different product types and shares data correspondingly with the aim of helping the readers know how the market is distributed by type.

Chapter 5 segments the market by downstream industry, with data covers sales, revenue, and growth rate tracing back to 2018.

Chapter 6 is the analysis of the whole market industrial chain, ranging from upstream raw materials to downstream customers, with regional conflicts taken into consideration.

Chapter 7 elaborates on market dynamics. Factors that drive, challenge, or restrain the market are all listed, together with industry news, opportunities, impacts of COVID-19, and SWOT analysis.

Chapter 8 shows the breakdown data at the regional level, which enables the readers to picture the regional competitive pattern of the market and learn about the revenue, sales, and market share of all the major regions.

Chapter 9-13 focus on each and every of the major region, specifically, North America, Europe, Asia Pacific, Latin America, Middle East & Africa. Sales, price, revenue, gross, gross margin, among others, will be all be presented.

Chapter 14 forecasts the future trend of the market not only as a whole but also from the perspective of all segments.

Years considered for this report:

Historical Years:

2018-2022

Base Year:

2022

Estimated Year:

2023

Forecast Period:

2023-2029